http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b4832c4247b76ebb2b0662cb10ea1bf7
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Sparreboom |
| name | Alex Sparreboom |
| given-name | Alex |
| organization-name | Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, the Ohio State University, Columbus, OH, USA Department of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210; From the Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital, Rotterdam, and Department of Medical Oncology, University Hospital Groningen, Groningen, the Netherlands; and Gilead Sciences Inc, Boulder, CO. From the Department of Medical Oncology, Erasmus MC University Medical Center, Daniel den Hoed Cancer Center; Department of Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, the Netherlands; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden; and the Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN From the Cancer Therapeutics Branch, Laboratory of Pathology, Medical Oncology Clinical Research Unit, Laboratory of Cellular and Molecular Biology, and Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute; and National Institute of Dental and Craniofacial Research and the Departments of Diagnostic Radiology and Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD Clinical Pharmacology Research Core and Cancer Therapeutics Branch, National Cancer Institute, Bethesda, Maryland Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, 3075 EA Rotterdam, the Netherlands. 2Laboratory of Translational and Molecular Pharmacology, Rotterdam, the Netherlands Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, MD; The Department of Medical Oncology, Erasmus University Medical Center–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD Authors' Affiliations: Departments of 1Medical Oncology, 2Clinical Chemistry, 3Trials and Statistics, and 4Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands; 5Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee; and 6Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden; Authors' Affiliations: Departments of 1Medical Oncology, 2Clinical Chemistry, 3Trials and Statistics, and 4Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands; 5Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee; and 6Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden 2Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 5Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio. From the Department of Medical OncologyRotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, Rotterdam, the Netherlands; and SmithKline Beecham Pharmaceuticals, Harlow, Essex, United Kingdom. Departments of aPharmaceutical Sciences, Authors' Affiliations: 1Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen; 2Institute of Pharmacy, Department of Pharmacology, University of Tübingen; 3Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen; 4Institute of Experimental and Clinical Pharmacology, 5Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel; 6Institute of Anatomy and Cell Biology, University of Würzburg, Würzburg, Germany; and 7Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee Division of Pharmaceutics and Pharmaceutical Chemistry College of Pharmacy The Ohio State University Columbus Ohio USA 1Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio. Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN Authors' Affiliations: 1Medizinische Klinik und Poliklinik D, Experimentelle Nephrologie, and 2Klinik und Poliklinik für Urologie, Universitätsklinikum Münster, Münster, Germany; Departments of 3Pharmaceutical Sciences and 4Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee; and 5Department of Medical Oncology, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands Medical Oncology Clinical Research Unit, National Cancer Institute, Bethesda;Department of Medical Oncology, Leiden University Medical Center, Leiden;Department of Medicine, Washington University, School of Medicine, St Louis;Beaufour Ipsen Pharma International, Paris;University of Leeds, Tom Connors Cancer Research Centre, Bradford;Department of Medical Oncology, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam, The Netherlands Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH 1Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee. Department of Medical Oncology, Erasmus University Medical Center Rotterdam – Daniel den Hoed Cancer Center, Rotterdam, The Netherlands From the Department of Medical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, the Netherlands From the Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital, Rotterdam, the Netherlands; Department of Medical Oncology, University Hospital Nijmegen, Nijmegen, the Netherlands; and IDEC Pharmaceuticals Corp, San Diego, CA. 2Medical Oncology Branch, Department of Clinical Chemistry, Antoni van Leeuwenhoek Huis, and Division of Molecular Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; Department of Pharmacokinetics and Drug Delivery, University Centre for Pharmacy, University of Groningen, Antonius Deusinglaan 2, 9713 AW Groningen, The Netherlands; and Department of Pharmacy, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands Authors' Affiliations: 1Department of Medical Oncology, Erasmus University Medical Center—Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; and 2Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee; Authors' Affiliations: 1Department of Medical Oncology, Erasmus University Medical Center—Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; and 2Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 10Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland 1Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital;; 2University of Tennessee Health Science Center, Memphis, Tennessee and Division of Pharmaceutics & Pharmaceutical Chemistry, College of Pharmacy & Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA From St Jude Children's Research Hospital; University of Tennessee, Memphis, TN; Cook Children's Hospital, Fort Worth, TX; and Aarhus University Hospital, Skejby, Denmark. Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy and Comprehensive Cancer Center Ohio State University Columbus Ohio USA Department of Pharmaceutical Sciences, St Jude Children’s Hospital, 332 North Lauderdale, DTRC, Mail Stop 313, Room I5308, Memphis, TN 38105, USA. Authors' Affiliation: Clinical Pharmacology Research Core, Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 3Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland From the Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek), University Hospital Rotterdam, the Netherlands. Authors' Affiliations: Departments of 1Medical Oncology and 2Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands; 3Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee; 4Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Missouri; 5Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden; 6Department of Biomedicine, Aarhus University, Aarhus; and 7Department of Pediatric Oncology and Hematology, Aarhus University Hospital, Skejby, Denmark Division of Pharmaceutics and Pharmacology College of Pharmacy and Comprehensive Cancer Center The Ohio State University Columbus Ohio USA From St Jude Children's Research Hospital, Memphis, TN; and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD. Authors' Affiliations: 1Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee and 2Department of Oncology, Johns Hopkins University, Baltimore, Maryland From the Department of Medical Oncology, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Institut Claudius-Regaud, Toulouse, France; and the Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX a Department of Medical Oncology, Erasmus MC University Medical Center Rotterdam—Daniel den Hoed Cancer Center, Rotterdam, The Netherlands; c Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA 2Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, National Cancer Institute, NIH, Bethesda, Maryland; and From the Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden, and Department of Medical Oncology, Erasmus MC–Daniel den Hoed, Rotterdam, the Netherlands. 4Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland; 2Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; and Division of Pharmaceutics and Pharmacology, College of Pharmacy, the Ohio State University, Columbus, OH, USA Authors' Affiliations: 1Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee; 2Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nuremberg, Erlangen, Germany; and 3Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands Authors' Affiliations: 1Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee; and From the Department of Medical OncologyRotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, Rotterdam, the Netherlands; and Rhône-Poulenc Rorer, Antony, France. National Cancer Institute, Clinical Pharmacology Research Core, Building 10, Room 5A01, 9000 Rockville Pike, Bethesda, MD 20892, USATel.: ;Fax: ;E-mail:; Erasmus University Medical Center, Department of Medical Oncology, 3075 EA Rotterdam, the Netherlands Authors' Affiliation: Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 1National Cancer Institute, Bethesda, Maryland; Division of Pharmaceutics and Pharmacology College of Pharmacy & Comprehensive Cancer Center The Ohio State University Columbus Ohio USA Authors' Affiliations: 1Clinical Pharmacology Program, 2SAIC-Frederick, National Cancer Institute (NCI), Frederick; 3Medical Oncology Branch, Center for Cancer Research, NCI, Bethesda, Maryland; 4Laboratory of Respiratory Biology, National Institute of Environmental Health Science, Durham, North Carolina; 5Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee; 6Biostatistics and Data Management Section, and 7Molecular Pharmacology Section, Center for Cancer Research, NCI; 8Cardiovascular Branch, National Heart Lung and Blood Institute, Bethesda, Maryland; and 9Quintiles Transnational Corporation, Research Triangle Park, North Carolina Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee From the Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, Rotterdam, the Netherlands. Division of Pharmaceutics and Pharmaceutical Chemistry and Comprehensive Cancer Center College of Pharmacy The Ohio State University Columbus Ohio USA Authors' Affiliations: 1Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center, Rotterdam, the Netherlands; 2Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee; Authors' Affiliations: 1Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center, Rotterdam, the Netherlands; 2Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 1Clinical Pharmacology Research Core, 4Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, Ohio. 5Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee From St Jude Children's Research Hospital; University of Tennessee Health Science Center, Memphis, TN; University of California, San Francisco, CA. Division of Pharmacokinetics and Drug Therapy Uppsala University, Uppsala; Department of Medical Oncology, Erasmus MC‐Daniel den Hoed Cancer Center Rotterdam Authors' Affiliations: 1Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands; 2Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee; and 3Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Missouri; Authors' Affiliations: 1Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands; 2Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee; and 3Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Missouri Authors' Affiliations: Departments of 1Pharmaceutical Sciences and 2Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee; and 3School of Biomedical Sciences, Curtin University, Perth, Australia 2Clinical Pharmacology Research Core; Clinical Pharmacology Research Core, SAIC‐Frederick, Frederick, Md;Department of Medical Oncology, Erasmus MC‐Daniel den Hoed Cancer Center/Josephine Nefkens Institute;Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands;Department of Oncology, University of Leuven, Leuven, Belgium;Departments of Chemistry and Medical Oncology, University of Antwerp, Antwerp, Belgium;The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Md;Medical Oncology Branch and Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Md. National Cancer Institute, The National Institutes of Health, Bethesda, MD 1Clinical Pharmacology Research Core; Division of Pharmaceutics and Pharmaceutical Sciences College of Pharmacy and Comprehensive Cancer Center The Ohio State University Columbus Ohio USA From the Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; the Department of Oncology, University Hospital Gasthuisberg, Leuven, Belgium; and Aventis Pharma, Antony Cedex, France; present address: National Cancer Institute, Bethesda, MD (A.S.) Authors' Affiliations: Departments of 1Pharmaceutical Sciences, 2Pathology, and 3Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee Author's Affiliation: Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital a Department of Medical Oncology, Erasmus University Medical Center Rotterdam–Daniel den Hoed Cancer Center, Rotterdam, The Netherlands Erasmus MC University Medical Center Rotterdam—Daniel den Hoed Cancer Center, Rotterdam and Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, MD 3Clinical Pharmacology Research Core, and; 5Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; and National Cancer Institute, Bethesda, MD Division of Pharmaceutics and Pharmacology College of Pharmacy The Ohio State University Columbus Ohio USA From the Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, MD St Jude Children's Research Hospital, Memphis, TN Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee; Authors' Affiliations: 1Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee; 2Curtin Health Innovation Research Institute, Western Australian Biomedical Research Institute, School of Biomedical Sciences, Curtin University of Technology, Perth, Australia; and 3Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands 2Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, National Cancer Institute, NIH, Bethesda, Maryland Department of Medical Oncology, Erasmus Medical Center—Daniel den Hoed Cancer Center, and Department of Clinical Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands;Division of Experimental Therapeutics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore;Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, National Cancer Institute, Bethesda, Md, USA Authors' Affiliations: 1Department of Medical Oncology, Erasmus University Medical Center–Daniel den Hoed Cancer Center, Rotterdam; 2Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands; 3Department of Pharmaceutical Biosciences, Uppsala University, Uppsala; 4Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 5Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee; and 6Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Authors' Affiliations: 1Department of Medical Oncology, Erasmus University Medical Center–Daniel den Hoed Cancer Center, Rotterdam; 2Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands; 3Department of Pharmaceutical Biosciences, Uppsala University, Uppsala; 4Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 5Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee; and 6Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy 1Clinical Pharmacology Program, Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands From the Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, Rotterdam, the Netherlands; and Department of Medical Oncology and Clinical Pharmacology, Tumor Biology Center, and Department of Internal Medicine, University Medical Center, Albert-Ludwigs University Freiburg, Freiburg im Breisgau, Germany. Departments of Medical Oncology and Clinical Chemistry, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam;Division of Experimental Therapeutics, The Sidney Kimmel ComprehensiveCancer Center at Johns Hopkins, Baltimore a Department of Medical Oncology, Erasmus MC – Daniel den Hoed Cancer Center, Rotterdam, The Netherlands; b Department of Clinical Chemistry, Rotterdam, The Netherlands Authors' Affiliations: Departments of 1Medical Oncology, 2Clinical Chemistry, and 3Trials and Statistics, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; 4Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee; and 5Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden; Authors' Affiliations: Departments of 1Medical Oncology, 2Clinical Chemistry, and 3Trials and Statistics, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; 4Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee; and 5Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden 1Medical Oncology and Daniel den Hoed Cancer Center, Departments of 1Department of Medical Oncology, Erasmus University MC–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands, and 4Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland From the Clinical Trials Unit, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis; Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit; Center for Cancer Research; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda; and Developmental Therapeutics Program, SAIC Frederick Inc, National Cancer Institute at Frederick, Frederick, MD Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN 38105; 1From the Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee. From the Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands. 2Division of Pharmaceutics, College of Pharmacy & Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 1Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital;; 2University of Tennessee Health Science Center, Memphis, Tennessee; 1Department of Medical Oncology, Erasmus MC–Daniel den Hoed Cancer Centre, Rotterdam, the Netherlands; 2Medical Oncology Clinical Research Unit, and Authors' Affiliations: Departments of 1Pharmaceutical Sciences and Department of Medical Oncology Erasmus MC Cancer Institute 's‐Gravendijkwal 230 3015CE Rotterdam; Department of Pharmaceutical Sciences St Jude Children's Research Hospital 262 Danny Thomas Place 38105‐3678 Memphis TN USA 3Department of Medical Oncology, Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, the Netherlands;; 7Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland 2Department of Medical Oncology, Erasmus University Medical Center–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands From the Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy; and Department of Medical Oncology, Rotterdam Cancer Institute, Rotterdam, the Netherlands. From the Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital, Rotterdam, and Department of Medical Oncology, University Medical Center St Radboud Nijmegen, Nijmegen, the Netherlands; and Institute of Cancer Research, Surrey, and AstraZeneca, Alderley Park, United Kingdom. 3College of Pharmacy & Comprehensive Cancer Center, Ohio State University, Columbus, Ohio. Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN Division of Pharmaceutics and Pharmacology, College of Pharmacy & Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Authors' Affiliations: 1Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, the Netherlands; 2Department of Internal Medicine, Catharina Hospital, Eindhoven, the Netherlands; 3Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden; and 4Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee; Authors' Affiliations: 1Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, the Netherlands; 2Department of Internal Medicine, Catharina Hospital, Eindhoven, the Netherlands; 3Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden; and 4Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee |
Incoming Links
Total number of triples: 395.